Kerri-Ann Millar - Aug 23, 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Kerri-Ann Millar by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Aug 23, 2021
Transactions value $
-$8,400
Form type
4
Date filed
10/5/2021, 07:21 PM
Next filing
Mar 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise $0 +6.67K +115.63% $0.00 12.4K Aug 23, 2021 Direct F1
transaction CUE Common Stock Tax liability $0 -1.96K -15.77% $0.00 10.5K Aug 23, 2021 Direct
transaction CUE Common Stock Options Exercise $9.38K +1.25K +11.95% $7.50 11.7K Oct 1, 2021 Direct F2
transaction CUE Common Stock Sale -$17.8K -1.25K -10.67% $14.21 10.5K Oct 1, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Restricted Stock Units Options Exercise $0 -6.67K -50% $0.00 6.67K Aug 23, 2021 Common Stock 6.67K Direct F4, F5
transaction CUE Stock Option (right to buy) Options Exercise $0 -1.25K -2.27% $0.00 53.7K Oct 1, 2021 Common Stock 1.25K $7.50 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.46, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 Each restricted stock unit award represents a contingent right to receive one share of common stock.
F5 Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020.
F6 The option vests in eight equal semi-annual installments beginning March 25, 2018.